28/6/2025–|Last update: 18:37 (Mecca time)
Hundreds of pancreatic problems associated with weight loss injections and diabetes, prompting UK health officials to launch a new study on side effects.
Some cases of inflammatory pancreatitis, which are associated with GLP-1 drugs (tacit bitchlid receptors similar to glucagon-1), were fatal.
Data issued by the Medicines and Healthcare Products Authority (MHRA) shows that since the license of these drugs, hundreds of cases of acute and chronic pancreatitis have been recorded among people taking GLP-1.
This includes:
- 181 cases reported from acute and chronic pancreatitis are linked to Terzopatide (the active component of Mongaro). 5 people died.
- 116 reaction of this type associated with the pyroGD, one of which was fatal.
- 113 cases of acute and chronic pancreatitis associated with Simajlotide (the active ingredient of Osimbick and Ugopi). One person died.
- 101 reaction of this type associated with oxenide, 3 people died.
- 52 reaction to this type is linked to dollateide, and 11 reaction to lixescinoids. No deaths were linked to any of these two medicines.
These cases are not confirmed that they are caused by the medications, but the person who reported it was suspected.
However, the Yellow Card Biobank project, launched by the MHRA, in cooperation with the “Genomix Engeland” in the UK, will examine whether the Pancreatitis associated with GLP-1 may be affected by the genetic composition of people.
Patients will be asked to provide more information and a saliva sample that will be evaluated to explore whether some people are at a higher risk of acute pancreatitis when taking these medications due to their genes.
The GLP-1 risks can reduce blood sugar levels in people with type 2 diabetes, and can also be prescribed to support some people in weight loss.
1.5 million people in the United Kingdom
Recent estimates indicate that about 1.5 million people in the UK are consuming weight loss injections. Health officials have suggested that they could help in obesity, but they confirmed that it is not a magic solution and has side effects.
Most of the side effects associated with injection are digestive problems that include nausea, constipation and diarrhea. The Medicines Regulatory Authority has recently warned that Montagro might make oral pills less effective in some patients.
“Evidence shows that nearly a third of the side effects of the drugs can be prevented by entering the genetic examination, and it is expected that the harmful pharmaceutical interactions (NHS) is expected to cost more than 2.2 billion pounds annually in hospitals alone.”
She added, “Information from Yellow Card Baybank will help us better than to the most at risk of negative interactions, which enables patients all over the UK to obtain the safest medicine for them, based on their genetic composition.”
She concluded: “To help us help you, we ask anyone who was hospitalized due to acute pancreatitis while taking GLP-1 to inform us of this through our” Yellow Card “system. Even if the criteria of this stage do not meet the study of” Bioprick “, the information about your reaction to the drug is always very valuable in helping to improve patient safety.”
“The GLP-1 drugs like Ozimbeck and Wigvophovi top the headlines, but like all medications, there may be a danger from serious side effects,” said Professor Matt Brown, the chief scientific official at Genomex Engeland.
He continued: “We believe that there is a real possibility to reduce these effects, as many negative reactions have a genetic cause. This step is in our partnership with the Medicines Regulatory and Health Care Authority (MHRA) will generate data and evidence for safer and more effective treatment through a more specialized approach to prescriptions, and support the shift towards a health care system that increases increasingly focused on prevention.”